Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target

International Journal of Gynecological Cancer

Volumn 20, Issue 2, 2010, Pages 212-219

  Suzuki, Nao ^a   Yoshioka, Norihito ^a   Uekawa, Atsushi ^a   Matsumura, Noriomi ^b   Tozawa, Akiko ^a   Koike, Jyunki ^a   Konishi, Ikuo ^b   Kiguchi, Kazushige ^a   Ishizuka, Bunpei ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cell proliferation; Clear cell adenocarcinoma of the ovary; Lysophosphatidic acid; Molecular targeting therapy; POU6F1

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR POU6F1; UNCLASSIFIED DRUG; ENPP2 PROTEIN, HUMAN; INORGANIC PYROPHOSPHATASE; MULTIENZYME COMPLEX; PHOSPHODIESTERASE I; POU6F1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR POU;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CELL NUCLEUS; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GENE CLUSTER; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNET; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR XENOGRAFT; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; DNA MICROARRAY; MALE; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MULTIENZYME COMPLEXES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PHOSPHODIESTERASE I; POU DOMAIN FACTORS; PYROPHOSPHATASES; RECEPTORS, LYSOPHOSPHATIDIC ACID; RNA, SMALL INTERFERING;

EID: 85047686643     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c97ae0     Document Type: Article

References (22)

1. Enomoto T, Kuragaki C, Yamasaki M, et al. Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol. 2003;22:447.
2. Scully RE, Young RH, Clement PB. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosai J, ed. Atlas of Tumor Pathology. 3rd Series. Fascicle 23. Washington, DC: Armed Forces Institute of Pathology; 1999:27-50.
3. Kobayashi H, Yamada Y, Kanayama S, et al. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2009;19:471-479.
4. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary, a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
5. Takano M, Sugiyama T, Yaegashi N, et al. Progression-free survival and overall survival of patients with clear cell adenocarcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol. 2007;12:256-260.
6. Gynecologic Cancer Intergroup/Japanese Gynecologic Oncology Group 3017. A randomized comparative study of paclitaxel + carboplatin (TC) therapy and irinotecan + cisplatin (CPT-P) therapy as the initial postsurgery chemotherapy in patients with clear cell adenocarcinoma of the ovary (randomized phase III trial) http://www.jgog.gr.jp/clinical-testing/pdf/JGOG-3017pdf.
7. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369-1374.
8. Suzuki N, Higashiguchi A, Hasegawa Y, et al. Loss of integrin 3 expression is associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Hum Cell. 2005;18:147-155.
9. Nozawa S, Tsukazaki K, Sakayori M, et al. Establishment of a human ovarian clear cell carcinoma cell line (RMG-I) and its single cloning. Hum Cell. 1988;1:426-434.
10. Aoki D, Suzuki N, Susumu N, et al. Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma. Hum Cell. 2005;18:143-146.
11. Miotti S, Tomassetti A, Facetti I, et al. Simultaneous expression of Caveolin-1 and E-cadherin in ovarian Ca cells stabilizes adherens junctions through inhibition of src-related kinases. Am J Pathol. 2005;167:1411-1427.
12. Sanna E, Miotti S, Mazzi M, et al. Binding of nuclear caveolin-1 to promoter elements of growth-associated genes in ovarian carcinoma cells. Exp Cell Res. 2007;313:1307-1317.
13. Yoshioka N, Suzuki N, Uekawa A, et al. POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary. Hum Cell. 2009;22:94-100.
14. Cordes N, Frick S, Brunner TB, et al. Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1. Oncogene. 2007;26:6851-6862.
15. Wey E, Schä fer BW. Identification of novel DNA binding sites recognized by the transcription factor mPOU (POU6F1). Biochem Biophys Res Commun. 1996;220:271-279.
16. Matsumura N, Huang Z, Baba T, et al. Yin yang 1 modulates taxane response in surface epithelial ovarian cancer. Mol Cancer Res. 2009;7:210-220.
17. Okamoto K, Wakayama M, Noji S, et al. A novel class of murine POU gene predominantly expressed in central nervous system. J Biol Chem. 1993;268:7449-7457.
18. Itamochi H, Kigawa J, Sugiyama T, et al. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100:281-287.
19. Fang X, Schummer M, Mao M, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;1582:257-264.
20. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003;3:582-591.
21. Lee Z, Swaby RF, Liang Y, et al. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006;66:2740-2748.
22. Ohta H, Sato K, Murata N, et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003;64:994-1005.